Dear Colleagues,
Atherosclerotic cardiovascular diseases (ASCVDs) comprise the first leading cause of morbidity and mortality in developing and developed countries. Despite the great advances in pharmaceutical therapy, there is still an increasing need to further investigate their underlying pathophysiology and to develop more effective therapeutic strategies. Acute cardiovascular events due to atherosclerotic plaque progression and rupture have been linked to dyslipidemia and inflammation, including a wide variety of biochemical disorders. Not only low-density lipoprotein cholesterol (LDL-C), but other lipids are supposed to contribute to atherosclerosis progression. Lp(a) and low HDL-C are emerging as new determinants of ASCVDs. In parallel, a growing number of inflammatory agents (e.g., cytokines) have been involved in atherogenic processes. The complex cardiometabolic risk profile of dyslipidemia and inflammation is characteristic of many conditions (e.g., obesity, type-2 diabetes) and predisposes to ASCVDs. Early identification and screening tools for atherogenic dyslipidemia and low-grade inflammation could help to guide prompt interventions for primary and secondary prevention of ASCVDs, including pharmaceutical and non-pharmaceutical interventions (e.g., lifestyle modification, dietary supplements). The aim of this Special Issue is to attract high quality papers focusing on the contribution of novel lipid and inflammatory factors in the development and progression of atherosclerosis. Biomarkers and their modification will also be highlighted in this Special Issue, which will include data derived from experimental or clinical studies. New therapeutic strategies based on the molecular mechanisms of atherogenesis, dyslipidemia and/or inflammation are needed for the prevention and treatment of ASCVDs. Thereby, papers about established or novel medications, herbal medicine, lifestyle interventions which could apply for primary and secondary prevention of ASCVDs are highly attracted in this Special Issue. Those interventions may target several aspects of the pathophysiological mechanisms of ASCVDs or may summarize therapeutic regimes of other, non-cardiovascular diseases, with potential roles in the treatment of ASCVDs. A discussion of these novel therapies will contribute to improved survival and the quality of life for patients with ASCVDs.
Dr. Nikolaos P. E. Kadoglou
Guest Editor
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.